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Background: Dermatological disease significantly affects patient’s health-related quality of life (HrQoL). Skindex is
one of the most frequently used dermatology-specific HrQoL measures. Currently no Chinese version of Skindex is
available. The aim of this study was to translate and culturally adapt Skindex-29 and Skindex-16 into Chinese, and to
evaluate their reliability and validity.
Methods: Translation and cultural adaption were performed following guidelines for cross-cultural adaption of
health-related quality of life measures. Subsequently, a cross-sectional study was conducted in which patients
with dermatological disease (n = 225) were enrolled. The Chinese version of Skindex-29 and Skindex-16 and
Dermatology Life Quality Index (DLQI) were completed. Reliability was evaluated with internal consistency using
Cronbach’s alpha. Validity was evaluated using known-groups validity, convergent validity and factor structure
validity.
Results: There were both seven items of Skindex-29 and Skindex-16 requiring a second forward- and backward-
translation to achieve the final satisfactory Chinese version. The internal consistency reliability was high (range of
Cronbach’s alpha for the scales of Skindex-29 0.85-0.97, Skindex-16 0.86-0.96). Known-group validity was demonstrated
by higher scores from patients with inflammatory dermatosis than from patients with isolated skin lesions (P < 0.05).
Evidence of factor structure validity of the Skindex-29 and Skindex-16 was demonstrated by both exploratory factor
analysis that accounted for 68.66% and 77.78% of the total variance, respectively, and confirmatory factor analysis with
acceptable fitness into the expected three-factor structure.
Conclusion: This study has developed semantically equivalent translations of Skindex-29 and Skindex-16 into Chinese.
The evaluation of the instruments’ psychometric properties shows they have substantial evidence of reliability and
validity for use as HrQoL instruments in Chinese patients with dermatological disease.
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Health-related quality of life (HrQoL) in dermatological
patients has received growing recognition as measuring
the burden of skin disease on patients in the fields of
clinical practice, clinical trial, and healthcare manage-
ment. In China, however, less attention has been paid to* Correspondence: luchuanjian888@vip.sina.com
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unless otherwise stated.HrQoL of dermatological patients, and one of the main
reasons is a lack of suitable instruments in Chinese that
have been developed or adapted according to established
scientific attributes and criteria [1].
Skindex is one of the best dermatological instruments
to measure dermatology-specific HrQoL [2]. Skindex
was comprised of 61 items initially and was then modi-
fied to two brief versions known as Skindex-29 and
Skindex-16 [3-6]. The two versions have been exten-
sively studied and refined in different languages and
population samples. Skindex-29 was recommended as
one of the instruments of choice in dermatology [7],
and Skindex-16 was recognized as an accurate andis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and used in many studies of dermatological diseases
[8,9]. However, there is no Chinese version of Skindex
available.
In this study, we translated into Chinese and cross-
culturally adapted Skindex-29 and Skindex-16. Further-
more, assessment of psychometric properties was carried
out.
Methods
The study was carried out in two phases: translation,
and evaluation of psychometric properties. The study
was approved by the ethics committee of the Guangdong
Provincial Hospital of Chinese Medicine.
Translation
The translation methodology conformed to the guidelines
for cross-cultural adaption of health-related quality of life
measures [10]. There were 5 steps.
1. Forward-translation: Two bilingual translators whose
native language was Chinese independently
translated Skindex-29 and Skindex-16 into Chinese.
Then the two translators discussed their translations
and agreed on a reconciliation version defined as the
first Chinese version.
2. Backward-translation: Two bilingual, native speakers
of English who had no access to the original version
of Skindex-29 and Skindex-16 independently
translated the first Chinese version into English.
Then a reconciliation version was agreed by the two
backward-translation persons.
3. Review by original author: The first backward-
translation was reviewed by the original author of
Skindex-29 and Skindex-16 (MMC). The semantic
equivalent of each backward-translation item was
classified according to the following scale: (a)
Satisfactory agreement; (b) Almost satisfactory
agreement but one or two words uncertain; (c)
Doubtful translation. For items classified as (b) or
(c), the forward- and backward-translations were
refined. The original author reviewed them again.
When a satisfactory agreement with the backward-
translations was reached, the second Chinese version
was obtained.
4. Pre-testing: The second Chinese version was tested
on a pilot group of patients with skin disease. The
patients were all native speakers of Chinese. Each
item was performed face to face interviews to
determine whether it was acceptable and
comprehensible.
5. Production of final version: The final Chinese
version was produced after refining problematic
items encountered in pre-testing and proof-reading.Evaluation of psychometric properties
Sample
A cross-sectional, non-interventional study of dermato-
logical patients was conducted at the department of
dermatology of Guangdong Provincial Hospital of Chinese
Medicine from January to May 2013. Outpatients were re-
cruited according to the following inclusion criteria: (1) age
16 years or more; (2) confirmed diagnosis of dermato-
logical disease; (3) willingness to provide consent to partici-
pate. Subjects were administrated a set of questionnaires
and given enough time to self-complete the questionnaires.
Respondents who left greater than 25% of the items of any
instrument unanswered were excluded from the evaluation
phase. Subjects were categorized into those with isolated
skin lesions such as nevi, warts and those with inflamma-
tory dermatosis, such as psoriasis, acne.
Instruments
The measurement instruments included sociodemographic
items, the validated Chinese version of Dermatology Life
Quality Index (DLQI) and the final Chinese versions of
Skindex-29 and Skindex-16.
The sociodemographic items included age, gender, mari-
tal status, education level, smoking, drinking alcohol, co-
existing chronic disease, and duration of skin disease.
The DLQI is a 10-item brief questionnaire to assess the
quality of life impact of skin disease [11]. Its Chinese ver-
sion has been evaluated to have good psychometric prop-
erties [12]. It is designed as 6 aspects of quality of life:
symptoms and feelings, daily activities, leisure, work and
school, personal relationships and bother with treatment,
while its unidimensionality has been proved for several
language versions and a total score of DLQI is generally
recommended to be used [13]. Items are answered on a 4-
point ordinal scale ranging from 0 to 3, and item scores
are summed to yield a total score (0–30).
Skindex-29 contains 30 items, while item 18 about side-
effects of treatment is not scored. It covers 3 scales: symp-
toms, emotions and functioning. Each item is rated on a
5-point Likert scale (never, rarely, sometimes, often, all the
time). All responses are transformed to a linear scale of
100 ranging from 0 to 100, and the scale score is regarded
as the mean of a patient’s responses to the items in a given
scale. Skindex-16 contains 16 items with each rated on a
7-point Likert scale. Scores for the emotions, symptoms
and functioning scales are also expressed in a linear scale
from 0 to 100, and the scoring method is the same with
those of Skindex-29.
For all the three instruments used, higher scale scores
reflect greater impairment.
Statistical analysis
For each scale of the Skindex-29 and Skindex-16, the
floor and ceiling effects were assessed. If more than 20%
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score, the floor or ceiling effects exist [14].
For reliability analysis, Cronbach’s alpha coefficient was
determined to assess internal consistency reliability.
Based on the hypotheses that patients with inflammatory
dermatosis would have higher scale scores than patients
with isolated skin lesions, known-groups validity was
assessed by comparison between the two groups using Wil-
coxon rank sum test. For Skindex-29, known-groups validity
was also assessed by comparison among different frequency
groups of bother from side-effects of treatment (measured
by item 18), and the Kruskal-Wallis H test was used.
Convergent validity assessed the degree to which the
Skindex-29 and Skindex-16 were similar to (converged
on) other measures that they should theoretically be re-
lated to. Spearman’s rank correlation coefficient was
used to assess correlations between the Skindex-29,
Skindex-16 and the DLQI.
Factor structure validity was assessed by extracting fac-
tors using exploratory factor analysis (EFA) with principal
components method. As substantial correlation between
factors was expected, oblique rotation was performed. Fac-
tors were identified based on eigenvalues greater than 1. A
criterion of highest factor loading, above 0.4 and at least
0.1 stronger than the next was used to identify items that
were salient in defining a given factor. Each factor was la-
beled by the heavily loaded items according to the aboveTable 1 Original and the first backward-translations of seven
classification of semantic equivalence
Original F
tr
Skindex-29 11. My skin condition affects
how close I can be
with those I love
M
p
12. I am ashamed of my skin condition B
I








19. My skin is irritated M
23. I am frustrated by my skin condition M
28. I am annoyed by my skin condition M
Skindex-16 4. Your skin condition being irritated Y
5. The persistence/reoccurrence of your skin condition Y
6. Worry about your skin condition (For example: that it
will spread, get worse, scar, be unpredictable, etc.)
Y
d
8. Frustration about your skin condition Y
10. Being annoyed about your skin condition Y
14. Your skin condition making it hard to show affection Y
y
15. The effects of your skin condition on your daily activities Ycriterion. Confirmatory factor analysis (CFA) was also
used to evaluate goodness of fit of the supposed three-
domain structure of the instruments. The goodness of fit
indices valued between 0 and 1 included goodness of fit
index (GFI), adjusted goodness of fit index (AGFI), non-
normed fit index (NNFI) and comparative fit index (CFI),
standardized root mean square residual (SRMR), and root
mean square error of approximation (RMSEA). The first
four indices were expected to be larger than 0.90, the
SRMR was expected to be less than 0.08, and the RMSEA
was expected to be less than 0.10 [15,16].
All the analysis was performed using SPSS 17.0 (SPSS
Inc., Chicago, IL, USA) and LISREL 8.8 (Scientific Soft-
ware International, Chicago, IL, USA).Results
Translation
The two forward-translators developed and agreed upon
the first Chinese versions of Skindex-29 and Skindex-16;
the two backward-translators translated and agreed on
the first versions into English, which were sent to and
reviewed by the original author (MMC).
There were 23 items of Skindex-29 and 9 items of
Skindex-16 classified as (a). The items that were classi-
fied as (b) or (c) were presented in Table 1 respectively




y skin condition affects my intimate
artner/spouse
c
ecause of my skin condition I feel that
lose face/don’t get respect
b
sing water affects my skin condition
.e. bathing, washing hands)
b
y skin condition makes it difficult to express my
motions/feelings
c
y skin is prickly/itchy b
y skin condition makes me feel dejected c
y skin condition makes me frustrated b
our skin is prickly/itchy b
our skin condition continuously or repeatedly erupts b
ou feel worried about your skin condition (i.e. the
isease will spread, worsen, leave scars, be uncontrollable)
b
ou feel dejected about your skin condition c
ou feel frustrated about your skin condition c
our skin condition makes it difficult to express
our emotions/feelings
c
our skin condition affects your daily life b
Table 2 The second backward-translations of three items
with c classification of the first backward-translations









17 My skin condition
makes it difficult
for me to express
love and affection.
a




Skindex-16 8 Your skin condition
makes you feel hopeless.
b
10 Your skin condition
makes you irritated.
a
14 Your skin condition
makes it difficult for
you to express love
and affection.
a
Table 3 Demographic characteristics of the sample
Characteristics Patients with inflammatory dermatos
Age, year, mean(SD)a 32.9(12.6)





Married or living with partner 95
Single 93
Separated or divorced 4
Widowed 0
Education level (%)c
Grade 9 or less 37
High school 59
College 81
Higher than college 15
Smoke, yes (%)b 34(17.7)
Drink wine, yes (%)b 56(29.2)
Exercise, yes (%)b 88(45.8)
Other chronic disease, yes (%)b 60(31.3)
BMI, mean(SD)a 22.1(3.7)
Duration, year, mean(SD)a 6.3(6.3)
SD, Standard Deviation; BMI, Body Mass Index.
aIndependent t test.
bPearson chi-square test.
cFisher 's exact test.
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ashamed”, “being annoyed” and “showing affection” were
particularly problematic.
A second forward- and backward-translation procedure
was performed for items with classification (b) and (c). The
original author reviewed the second backward-translation
of items with classification (c) and the results were pre-
sented in Table 2. For the item 23 of Skindex-29 and item 8
of Skindex-16 classified as (b), there is no Chinese word
that means precisely the same with “being frustrated”. Fi-
nally, a phase was used to express the concept to achieve
satisfactory agreement with the original instruments. Then
the second Chinese version of the questionnaires was de-
veloped, and it was tested on a panel of 10 patients with
dermatological disease aged from 20 years to 68 years old.
There were no problems with comprehension of all the
items. The final version was produced after a proof-reading.
Psychometric properties
Sample characteristics
A total of 225 patients with dermatological disease were
enrolled. The mean age of participants was 32.5 years

































Chinese version of Skindex-29
Emotions 10(0–100) 49.0 25.0 30.0 50.0 67.5 3.2 0.9 0.63-0.82 0.94
Symptoms 7(0–100) 37.2 21.1 17.9 35.7 53.6 3.2 0.0 0.50-0.67 0.85
Functioning 12(0–100) 36.8 24.6 14.6 35.4 55.2 5.0 0.0 0.56-0.84 0.95
Total 29(0–100) 41.1 22.1 23.7 40.5 55.2 1.4 0.0 0.50-0.83 0.97
Chinese version of Skindex-16
Emotions 7(0–100) 54.4 31.1 28.6 54.8 83.3 2.8 11.1 0.73-0.88 0.94
Symptoms 4(0–100) 36.2 28.2 12.5 29.2 50.0 8.3 3.7 0.62-0.78 0.86
Functioning 5(0–100) 36.1 30.1 6.7 30.0 60.0 15.3 6.5 0.83-0.88 0.94
Total 16(0–100) 44.3 27.2 21.4 42.7 64.6 2.3 2.3 0.60-0.85 0.96
SD, Standard Deviation.
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80% were at least high school educated and 31% suffered
from other chronic diseases. The mean duration of der-
matological disease was 6.1 years (standard deviation =
6.5). There were 192 patients with inflammatory derma-
tosis and 33 patients with isolated skin lesions. From the
results of independent t test/Pearson chi-square test/
Fisher’s exact test, all the demographic characteristics of
the two groups were not significantly different at the sig-
nificant level 0.05. Further information of the patients
are summarized in Table 3. Out of these, 4 patients had
more than 25% of items of Skindex-29 missing, and 9
patients had more than 25% of items of Skindex-16
missing. Hence, the analysis of Skindex-29 and Skindex-
16 was carried out on 221 (98%) and 216 (96%) patients
respectively.Table 5 Variations in total and scale scores of Skindex-29 and
and patients with isolated skin lesions
Patients with inflammatory dermatoses mean ± SD
Skindex-29
N 191
Emotions 52.13 ± 23.98
Symptoms 39.93 ± 20.46
Functioning 38.66 ± 24.11
Total 43.61 ± 21.43
Skindex-16
N 190
Emotions 57.32 ± 30.42
Symptoms 38.56 ± 27.49
Functioning 37.65 ± 30.84
Total 46.48 ± 26.55
SD, Standard Deviation.Response distribution and reliability
The means, standard deviations, percentiles, corrected item-
total correlations, and Cronbach’s alpha coefficients are pre-
sented in Table 4 for Skindex-29 and Skindex-16 and their
scales. All scales of Skindex-29 had small floor and ceiling
effects (≤5%), while emotions and functioning scales of
Skindex-16 had mild floor and ceiling effects (>10%). The
Cronbach’s alpha coefficients of Skindex-29 and Skindex-16
and their scales were high (>0.80), and the item-total correl-
ation ranged from 0.5 to 0.88, which signified very good
internal-consistency reliability of the two instruments.
Known-group validity
Patients with inflammatory dermatosis had significantly
higher scale and total scores of Skindex-29 and Skindex-
16 compared with patients with isolated lesions (Table 5).Skindex-16 in patients with inflammatory dermatosis
Patients with isolated lesions mean ± SD P value
30
29.17 ± 22.09 <0.001
19.70 ± 16.74 <0.001
25.13 ± 24.91 0.005
25.20 ± 20.07 <0.001
26
33.04 ± 27.80 <0.001
16.19 ± 22.74 <0.001
24.36 ± 29.09 0.039
26.08 ± 23.46 <0.001
Figure 1 Box plot of Skindex-29 total scorein patients with various grades of bothered by the side-effects of treatment.
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treatment, there were 30 patients never worried, 35 pa-
tients rarely worried, 66 patients sometimes worried, 55
patients often worried and 35 patients worried all the
time. The total score of Skindex-29 showed significantly
different among the five groups (Kruskal-Wallis H test
Chi-square = 93.39, P < 0.001) and increased with the in-
creasing concern of side-effects (Figure 1).Convergent validity
It was demonstrated that moderate to good correlations
between Skindex-29 and DLQI, Skindex-16 and DLQI
(Skindex-29, r from 0.43 to 0.84; Skindex-16, r from 0.39
to 0.83) (Table 6).Table 6 Spearman’s rank correlation coefficients between Ski
DLQI Symptoms and feelings Daily activities
Skindex-29
Emotions 0.75 0.63 0.62
Symptoms 0.64 0.57 0.58
Functioning 0.84 0.64 0.70
Total score 0.83 0.67 0.70
Skindex-16
Emotions 0.70 0.64 0.58
Symptoms 0.60 0.58 0.55
Functioning 0.83 0.63 0.70
Total score 0.81 0.70 0.69
DLQI, Dermatology Life Quality Index.
P < 0.001 for all.Factor structure validity
Exploratory factor analysis using eigenvalues greater than 1
as the criterion resulted in 4 factors for Skindex-29 and 3
factors for Skindex-16, which accounted for 68.66% and
77.78% of the total variances, respectively. With oblique ro-
tation method, the factor loadings of Skindex-29 and
Skindex-16 are presented in Tables 7 and 8. For Skindex-
29, the first, second and fourth factors matched almost the
three original scales: Functioning, Emotion and Symptoms.
The third factor, however, seemed as the combination of
items originally belonging to the Function and Symptoms.
For Skindex-16, the extracted three factors reflected almost
perfectly the original scales of functioning, emotion and
symptoms. And the factor loadings ranged from 0.799 to
0.969 for factor 1 (functioning), 0.459 to 0.998 for factor 2ndex-29 and Dermatology Life Quality Index
Leisure Work and school Personal relationship Treatment
0.66 0.46 0.43 0.51
0.54 0.62 0.72 0.62
0.72 0.59 0.67 0.62
0.71 0.51 0.61 0.55
0.58 0.52 0.51 0.48
0.47 0.44 0.41 0.39
0.75 0.64 0.71 0.57
0.69 0.61 0.62 0.56










2. My skin condition affects how well I sleep 0.056 0.014 0.779 −0.079
4. My skin condition makes it hard to work or do
hobbies
0.327 0.183 0.583 −0.106
5. My skin condition affects my social life 0.624 0.168 0.117 0.077
8. I tend to stay at home because of my skin condition 0.556 0.153 0.173 0.055
11. My skin condition affects how close I can be with
those I love
0.776 −0.189 0.260 0.032
14. I tend to do things by myself because of my skin
condition
0.703 0.052 0.051 0.115
17. My skin condition makes showing affection difficult 0.785 −0.091 0.094 0.148
20. My skin condition affects my interactions with
others
0.766 0.105 −0.012 0.124
22. My skin condition is a problem for the people I
love
0.522 0.082 0.322 0.006
25. My skin condition affects my desire to be with
people
0.667 0.205 0.045 −0.030
29. My skin condition interferes with my sex life 0.664 −0.383 0.517 0.009
30. My skin condition makes me tired 0.281 0.479 0.298 −0.052
Emotion
3. I worry that my skin condition may be serious 0.129 0.445 0.384 0.030
6. My skin condition makes me feel depressed 0.266 0.636 0.145 −0.141
9. I worry about getting scars from my skin condition 0.251 0.710 −0.464 0.146
12. I am ashamed of my skin condition 0.747 0.299 −0.148 −0.016
13. I worry that my skin condition may get worse 0.179 0.626 0.068 −0.022
15. I am angry about my skin condition 0.325 0.540 −0.050 0.080
21. I am embarrassed by my skin condition 0.649 0.387 −0.148 −0.010
23. I am frustrated by my skin condition 0.423 0.515 0.050 −0.094
26. I am humiliated by my skin condition 0.808 0.213 −0.228 0.033
28. I am annoyed by my skin condition 0.271 0.680 0.129 −0.233
Symptoms
1. My skin hurts 0.010 0.077 0.237 0.573
7. My skin condition burns or stings 0.045 −0.079 0.517 0.475
10. My skin itches −0.058 0.112 0.736 0.030
16. Water bothers my skin condition (bathing, washing
hands)
0.242 −0.063 −0.168 0.792
19. My skin is irritated −0.318 0.729 0.201 0.315
24. My skin is sensitive −0.325 0.633 0.430 0.113
27. My skin condition bleeds 0.158 0.154 0.026 0.547
Bold values indicate the largest factor loadings for each item.
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respectively.
Confirmatory factor analysis was also performed to
evaluate the factor structure validity of Skindex-29 and
Skindex-16 according to their original structure. The
goodness-of-fit indices are shown in Table 9, and thestructure graphs are shown in Figures 2 and 3 respect-
ively for Skindex-29 and Skindex-16. The two instru-
ments got similar results. The indices GFI, AGFI and
RMSEA were not as good as possible, but the NNFI and
CFI were large enough to meet the cut-off criterion of
goodness-of-fit indices (lager than 0.90). Meanwhile, the








12. The effects of your skin condition on your interactions with others
(For example: interactions with family, friends, close relationships, etc.)
0.969 −0.089 0.023
13. The effects of your skin condition on your desire to be with people 0.854 0.012 0.068
14. Your skin condition making it hard to show affection 0.964 −0.129 0.048
15. The effects of your skin condition on your daily activities 0.809 −0.031 0.141
16. Your skin condition making it hard to work or do what you enjoy 0.799 0.065 0.058
Emotion
5. The persistence/reoccurrence of your skin condition −0.194 0.836 0.257
6. Worry about your skin condition (For example: that it will spread,
get worse, scar, be unpredictable, etc.)
−0.210 0.998 0.030
7. The appearance of your skin condition 0.083 0.776 0.010
8. Frustration about your skin condition 0.500 0.578 −0.163
9. Embarrassment about your skin condition 0.613 0.459 −0.131
10. Being annoyed about your skin condition 0.267 0.742 −0.036
11. Feeling depressed about your skin condition 0.302 0.689 −0.005
Symptoms
1. Your skin condition itching −0.009 0.156 0.762
2. Your skin condition burning or stinging 0.092 −0.064 0.882
3. Your skin condition hurting 0.245 −0.128 0.769
4. Your skin condition being irritated −0.122 0.333 0.637
Bold values indicate the largest factor loadings for each item.
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was also satisfying (less than 0.08) [16].
Discussion
In this study, we translated Skindex-29 and Skindex-16
into Chinese according to accepted steps in the generation
of conceptually and linguistically equivalent translations of
quality of life measures. Our evaluation of the psychomet-
ric properties of the resulting Chinese versions of Skindex-
29 and Skindex-16 suggested that they are reliable and
valid measures of HrQoL in Chinese patients with derma-
tological disease.
Our translation steps were similar with those of other
language versions of Skindex-29 and Skindex-16 [17-20].
However, the evaluation of the backward translation and
the definition of the final version were completed by the
original author instead of a multidisciplinary committeeTable 9 Goodness-of-fit indices of three-factor structure
model for Skindex-29 and Skindex-16
GFI AGFI NNFI CFI SRMR RMSEA
(90%
Confidence interval)
Skindex-29 0.70 0.66 0.96 0.96 0.06 0.11 (0.10, 0.11)
Skindex-16 0.74 0.65 0.94 0.95 0.07 0.15(0.14, 0.17)suggested by the guidelines for cross-cultural adaption of
health-related quality of life measures [10], which might
lead to potential bias. During the translation process, some
words relating emotions, like “embarrassed”, “ashamed”,
“frustrated” became the most difficult and problematic
issue for expression in Chinese. The Chinese translation of
these words was modified until a satisfactory version was
created. Similar problem was encountered, for example, in
the development of Turkish version of Skindex-29 [18].
With respect to the reliability, the Cronbach’s alpha
coefficients for the global and three scales were all
greater than 0.80, which indicated satisfactory internal
consistency of the Chinese version of Skindex-29 and
Skindex-16. And the results were similar to those of
other language versions of Skindex-29 and Skindex-16
[17-20]. High item-total correlations further confirmed
the good homogeneity of the questionnaires. Mild floor
and ceiling effects were noted for the scales of function-
ing and emotions of Skindex-16, while no floor or ceiling
effect was observed for Skindex-29. It might suggest that
Skindex-16 provide limited information on bothering by
dermatological disease for those with low level of func-
tioning and high level of emotions.
Our results showed that the Chinese version of Skindex-
29 and Skindex-16 had good capacity to discriminate
Figure 2 The three-factor model for Skindex-29 obtained from confirmatory factor analysis.
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isolated lesions, which was consistent with the original ver-
sion and other language versions [17-20]. Furthermore, we
found a difference in the total score of Skindex-29 among
patients with different levels of being bothered by the side-
effects of treatment which was measured by the item 18 of
Skindex-29. The more bothered by the side-effects of treat-
ment, the worse quality of life patients had.
The pattern of correlation between Skindex-29 and
Skindex-16 scale scores and DLQI subscale scores pro-
vides available evidence of convergent validity. For allthree scales, they exhibited moderate to excellent corre-
lations with the six subscales of DLQI. The reasons of
choosing DLQI as the measures that Skindex should
theoretically be related to are that the DLQI is the most
commonly used HrQoL instruments in dermatology and
its Chinese version has been proved to be reliable and
valid [12,21].
The exploratory factor analysis yielded four factors for
Skindex-29 and three factors for Skindex-16. The result
of Skindex-29 was consistent with that of the Polish ver-
sion [22], but in contrast to the three-factor structure
Figure 3 The three-factor model for Skindex-16 obtained from confirmatory factor analysis.
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[4,23]. The differences between present results and the
results in the US and Italy samples might be partly due
to differences in sample characteristics. The results of
Skindex-16 were in accordance with the original version
and provided further confirmation of the three factors of
the instrument.
There has not been confirmatory factor analysis of
Skindex, and our results indicated that the three-factor
structure of Skindex-29 and Skindex-16 was acceptable.
The reason of low values of GFI and AGFI and high
value of RMSEA might be that they could be impacted
by the sample size which in this study was relatively
small [16].
There were some limitations in this study. The study
sample was from the outpatients of the department of
dermatology and the time consuming of completing the
questionnaire might lead to selection bias. To decrease
burden of the study on patients, test-retest reliability
was not evaluated. And responsiveness, i.e. the ability of
the instrument to detect small but meaningful changes
over time was not evaluated either because it was hard
to investigate clinical significant changes for many der-
matologic conditions enrolled in this study within a rea-
sonable time frame.Additional studies would include further validation
with patients from multi-center clinics, evaluation of
test-retest reproducibility and responsiveness of the
instruments. And international cooperative research
could be expected to use the Skindex to measure
HrQoL in patients with dermatological disease. In
addition, more information on patients from different
socio-cultural areas and environments would be desir-
able. In particular, using the original English version of
scale could have introduced response bias because of cul-
tural differences between the US and China. How the
Skindex might exhibit Differential Item Functioning (DIF)
among patients with different cultural background needs
further research.Conclusion
The Chinese versions of Skindex-29 and Skindex-16
have been developed and demonstrated to be reliable
and valid instruments for use as HrQoL instruments in
Chinese patients with dermatological disease. The Skin-
dex is expected to be adopted into clinical practice and
clinical trials to allow physicians to increase the atten-
tion paid to HRQoL of patients not only the symptoms
of dermatological disease.
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